ES2196632T3 - Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa. - Google Patents

Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa.

Info

Publication number
ES2196632T3
ES2196632T3 ES98961110T ES98961110T ES2196632T3 ES 2196632 T3 ES2196632 T3 ES 2196632T3 ES 98961110 T ES98961110 T ES 98961110T ES 98961110 T ES98961110 T ES 98961110T ES 2196632 T3 ES2196632 T3 ES 2196632T3
Authority
ES
Spain
Prior art keywords
complex
carragenine
pharmaceutical compositions
water soluble
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98961110T
Other languages
English (en)
Inventor
Carla Marcella Caramella
Maria Cristina Bonferoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharmaceuticals SRL
Original Assignee
Eurand International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand International SpA filed Critical Eurand International SpA
Application granted granted Critical
Publication of ES2196632T3 publication Critical patent/ES2196632T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un complejo de carragenina que tiene una viscosidad comprendida entre 500 y 2000 cPs medido a 37°C con una tasa de cizallamiento de 20 s exp(-1), con un medicamento en polvo soluble en agua con un tamaño de partículas medio que varía de 10 a 100 micrómetros y el medicamento básico soluble en agua está contenido en el complejo en cantidades que varían de 1, 5 a 5 mmol/g de carragenina.
ES98961110T 1997-10-29 1998-10-29 Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa. Expired - Lifetime ES2196632T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97PV000009A IT1297461B1 (it) 1997-10-29 1997-10-29 Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili

Publications (1)

Publication Number Publication Date
ES2196632T3 true ES2196632T3 (es) 2003-12-16

Family

ID=11397386

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98961110T Expired - Lifetime ES2196632T3 (es) 1997-10-29 1998-10-29 Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa.

Country Status (13)

Country Link
US (1) US6355272B1 (es)
EP (1) EP1030689B1 (es)
JP (1) JP2001521010A (es)
KR (1) KR20010031604A (es)
AT (1) ATE238070T1 (es)
AU (1) AU735337B2 (es)
BR (1) BR9813149A (es)
CA (1) CA2307863A1 (es)
DE (1) DE69813872T2 (es)
ES (1) ES2196632T3 (es)
IT (1) IT1297461B1 (es)
NZ (1) NZ504793A (es)
WO (1) WO1999021586A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US20030229158A1 (en) * 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
KR101132969B1 (ko) * 2001-11-13 2012-04-09 아스텔라스세이야쿠 가부시키가이샤 용해성 약물 지속 방출 시스템
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
AU2003245252A1 (en) * 2002-04-30 2003-11-17 Fmc Corporation Carrageenan based antimicrobial compositions
US8367098B2 (en) * 2002-04-30 2013-02-05 The Population Council, Inc. Unique combinations of antimicrobial compositions
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US20040091528A1 (en) * 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
KR101087464B1 (ko) * 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
CA2601716C (en) 2004-06-25 2011-05-31 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
CA2571554A1 (en) * 2004-06-28 2006-01-19 Alza Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
PT2262486E (pt) 2008-08-01 2013-03-27 Tovarna Zdravil D D Novo Mesto Krka Composição de quetiapina
JP2011068606A (ja) * 2009-09-25 2011-04-07 Kumamoto Univ 徐放性担体及び同徐放性担体を用いた薬剤並びに同薬剤を用いたドラッグデリバリーシステム
US9364549B2 (en) 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
US20130303632A1 (en) * 2012-05-10 2013-11-14 Fmc Corporation Controlled release solid dose form
WO2026042047A1 (en) * 2024-08-23 2026-02-26 Johnson & Johnson Vision Care, Inc. Compositions and articles comprising reversible complexes of crosslinked carrageenan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5227M (es) * 1966-03-18 1967-08-14
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
DK171716B1 (da) 1982-03-12 1997-04-07 Pharmacia & Upjohn Ab Fremgangsmåde til fremstilling af et kompleks af carrageenan og emepronium, doxycyklin eller propranolol
JPS60174729A (ja) 1984-02-21 1985-09-09 Nippon Shinyaku Co Ltd 抗癌医薬組成物
US4613497A (en) 1984-02-29 1986-09-23 Health Products Development, Inc. Dry, water-foamable pharmaceutical compositions
JPS61130239A (ja) 1984-11-30 1986-06-18 Dai Ichi Seiyaku Co Ltd 複合体
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
SE9103110D0 (sv) 1991-10-24 1991-10-24 Kabi Pharmacia Ab New drug formulation

Also Published As

Publication number Publication date
DE69813872D1 (de) 2003-05-28
WO1999021586A3 (en) 1999-07-08
ITPV970009A1 (it) 1999-04-29
CA2307863A1 (en) 1999-05-06
KR20010031604A (ko) 2001-04-16
EP1030689A1 (en) 2000-08-30
EP1030689B1 (en) 2003-04-23
ITPV970009A0 (it) 1997-10-29
AU1665199A (en) 1999-05-17
AU735337B2 (en) 2001-07-05
BR9813149A (pt) 2000-08-15
IT1297461B1 (it) 1999-12-17
US6355272B1 (en) 2002-03-12
JP2001521010A (ja) 2001-11-06
DE69813872T2 (de) 2004-02-26
WO1999021586A2 (en) 1999-05-06
ATE238070T1 (de) 2003-05-15
NZ504793A (en) 2002-03-01

Similar Documents

Publication Publication Date Title
SE9203594D0 (sv) Laekemedel i dispersa system
NO974404D0 (no) Insufflasjonsbærer for medikamenter med kontrollert frigivelse
EP1104288A4 (en) ORAL-DEGRADABLE TABLET WITH TRAINING OF TOOTH SLIME
MA27131A1 (fr) Systeme d'inhalation de poudre seche pour une administration transpulmonaire
ATE238070T1 (de) Komplex aus carrageenan und einem wasserlöslichen medikament mit einer spezifischen granulometrie und entsprechende pharmazeutische zusammensetzungen mit gesteuerter freisetzung
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
ES2196382T3 (es) Administracion y envase de medicamentos.
BR0009604A (pt) Formulações de goma de mascar sobre-revestidas
ATE464885T1 (de) Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe
MX167175B (es) Sistema de entrega de drogas, con liberacion controlada, para la bolsa periodontal
HUP0101545A1 (hu) Peptideket időben elnyújtva kibocsátó gyógyászati készítmények és eljárás az előállításukra
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
DE69803940D1 (de) Ophthalmische zusammensetzungen mit verlängerte freisetzung enthaltend im wasser lösliche arzneistoffe
DE69812887D1 (de) Mikropartikel aus chitosan-gelatin a
MX9602176A (es) Modafinilo teniendo tamaño de particulas definido.
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
ATE536869T1 (de) Auf glucan-film basierte wirkstoffverabreichungssysteme
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
AR018252A1 (es) Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral.
IL165835A0 (en) Modafinil pharmaceutical compositions
AR006087A1 (es) Forma de dosificación para la administración de clorhidrato de verapamil a una velocidad de liberación uniforme.
HUP9801414A2 (hu) Nátrium-alginátot és kálium-bikarbonátot tartalmazó folyékony vizes gyógyszerkészítmények
ATE295151T1 (de) Sprühbeschichtete mikropartikel für nadellose spritzen
AU1434700A (en) Dry powder pharmaceutical formulation
BR0007513A (pt) Fosfatidilinositóis sulfatados, sua preparação euso